CASI Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$3.22M
-0.1
-2.57
$28.54M
233
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.
emptyResult
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.
Recently from Cashu
CASI Pharmaceuticals Transitioning to OTC Markets: Pursuing Growth and Investor Engagement Opportunities
### CASI Pharmaceuticals Adjusts Course: Embracing New Opportunities on OTC Markets CASI Pharmaceuticals Inc. is undergoing a strategic transition as it announces its move to the OTC Markets Group fol…
CASI Pharmaceuticals Advances Cancer Treatment Innovations Through Strategic Research and Development
CASI Pharmaceuticals Advances in Oncology with New Drug Developments CASI Pharmaceuticals continues to make significant strides in the field of oncology, with a focus on bringing innovative therapies…
CASI Pharmaceuticals Pursues Strategic Partnerships to Advance Oncology Therapy Development
CASI Pharmaceuticals Explores Strategic Partnerships for Development of Novel Therapies CASI Pharmaceuticals focuses on advancing its oncology pipeline through potential strategic partnerships that co…
CASI Pharmaceuticals Submits NDA for Innovative Oncology Drug, Advancing Cancer Treatment Options
CASI Pharmaceuticals Advances in Oncology with New Drug Application CASI Pharmaceuticals, a biopharmaceutical company focused on innovative therapeutics for oncology, recently announces the submission…